A prospective, randomised multi-centre phase II study evaluating the adjuvant, neoadjuvant or palliative treatment with tamoxifen +/- GnRH analogue versus aromatase inhibitor + GnRH analogue in male breast cancer patients.
Read time: 1 mins
Last updated:17th Jan 2012
To determine the estradiol suppression between the three treatment arms after three months.
|Study start date||2012-01-17|